Growth inhibitory actions of prothrombin on normal hepatocytes: Influence of matrix

Cell Biology International

Volumn 31, Issue 9, 2007, Pages 929-938

  Carr, Brian I ^a   Kar, Siddhartha ^a   Wang, Meifang ^a   Wang, Ziqiu ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cell matrix; Hepatocyte growth; Prothrombin

Indexed keywords

COLLAGEN; DECARBOXYPROTHROMBIN; FIBRONECTIN; PROTHROMBIN; SCLEROPROTEIN; WARFARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXYLATION; CELL SHAPE; CONTROLLED STUDY; CYTOSKELETON; DEPOLYMERIZATION; DNA SYNTHESIS; EXTRACELLULAR MATRIX; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER REGENERATION; MALE; NONHUMAN; PARTIAL HEPATECTOMY; RAT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSKELETON; DNA; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR MATRIX; HEPATECTOMY; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; PROTHROMBIN; RATS; RATS, INBRED F344; VITAMIN K;

EID: 34249654071     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2007.03.001     Document Type: Article

References (75)

1. Antovic J., Djordjevic V., Kocic G., Koracevic D., Bjelakovic G., and Bakic M. Blood coagulation factors change during liver regeneration in rats. Arch Int Physiol Biochim Biophys 101 (1993) 357-359
2. Bhadriraju K., and Hansen L.K. Extracellular matrix- and cytoskeleton-dependent changes in cell shape and stiffness. Exp Cell Res 278 (2002) 92-100
3. Bissell D.M., and Choun M.O. The role of extracellular matrix in normal liver. Scand J Gastroenterol Suppl 151 (1988) 1-7
4. Bouzahzah B., Nishikawa Y., Simon D., and Carr B.I. Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. J Cell Physiol 165 (1995) 459-467
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
6. Carr B.I. Vitamin K inhibits hepatoma growth in vitro and in patients. Proc AACR 37 (1996) 1485
7. Carr B.I., Wang Z., Wang M., Kar S., Wilcox C.S., Rosi K., et al. A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo. J Mol Biol 326 (2003) 721-735
8. DiPersio C.M., Jackson D.A., and Zaret K.S. The extracellular matrix coordinately modulates liver transcription factors and hepatocyte morphology. Mol Cell Biol 11 (1991) 4405-4414
9. Ettore G.M., Sommacale D., Farges O., Saufanet A., Guevara O., and Belghiti J. Postoperative liver function after elective right hepatectomy in elderly patients. Br J Surg 88 (2001) 73-76
10. Farinati F., Pengo V., Bassi N., Naccarato R., and D'Amico D. Monitoring liver regeneration after right hepatectomy. Ital J Surg Sci 15 (1985) 75-77
11. Fasco M.J., Heldebrandt E.F., and Suttie J.W. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 257 (1982) 11210-11212
12. Furnival C.M., Mackenzie R.J., MacDonald G.A., and Blumgart L.H. The mechanism of impaired coagulation after partial hepatectomy in the dog. Surg Gynecol Obstet 143 (1976) 81-86
13. Giannelli G., Beramini C., Fransvea E., Marinosci F., Quaranta V., and Antonaci S. Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 81 (2001) 613-627
14. Grigioni W.F., Garbisa S., D'Errico A., Baccarini P., Stetler-Stevenson W.G., Liotta L.A., et al. Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol 138 (1991) 647-654
15. Gulubova M.V. Collagen type III and type IV detection in and around human hepatocellular carcinoma. Gen Diag Pathol 142 (1997) 155-163
16. Higgins G.M., and Anderson R.M. Experimental pathology of the liver: restoration of the liver following partial hepatectomy. Arch Pathol 12 (1931) 186-202
17. Hitomi M., Yokoyama F., Kita Y., Nonomura T., Masaki T., Yoshiji H., et al. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. Int J Oncol 26 (2005) 713-720
18. Hong J.T., and Glauert H.P. Effect of extracellular matrix on the expression of peroxisome proliferation associated genes in cultured rat hepatocytes. Toxicol In Vitro 14 (2000) 177-184
19. Huisse M.G., Leclerq M., Belghiti J., Flejou J.F., Suttie J.W., Bezeaud A., et al. Mechanism of the abnormal vitamin K-dependent gamma carboxylation process in human hepatocellular carcinomas. Cancer 74 (1994) 1533-1541
20. Jagirdar J., Ishak K.G., Colombo M., Brambilla C., and Paronetto F. Fibronectin patterns in hepatocellular carcinoma and its clinical significance. Cancer 56 (1985) 1643-1648
21. Kim S.H., Kim J.H., and Akaike T. Regulation of cell adhesion signaling by synthetic glycopolymer matrix in primary cultured hepatocyte. FEBS Lett 553 (2003) 433-439
22. Kim T.H., Kim E.K., Yoon D.W., Kim J., Rhim T.Y., and Kim S.S. Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis Lung Carcinoma tumor growth and metastases. Angiogenesis 5 (2002) 191-201
23. Kim T., Mars W.M., Stolz D.B., Petersen B.E., and Michalopoulos G.K. Extracellular matrix remodeling at the early stages of liver regeneration in the rat. Hepatology 26 (1997) 896-904
24. Kin M., Torimura T., Ueno T., Inuzuka S., and Tanikawa K. Sinusoidal capillarization in small hepatocellular carcinoma. Pathol Int 44 (1994) 771-778
25. Koukoulis G.K., Shen J., Virtanen I., and Gould V.E. Immunolocalization of cellular fibronectins in the normal liver, cirrhosis, hepatocellular carcinoma. Ultrastruct Pathol 19 (1995) 37-43
26. Kumar S., Haigh J.R., Tate G., Boothby M., Joanes D.N., Davies J.A., et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance. Br J Haematol 74 (1990) 82-85
27. Lamson D.W., and Plaza S.M. The anticancer effects of vitamin K. Altern Med Rev 3 (2003) 303-318
28. Laurell C.B. Electroimmuno assay. J Clin Invest 29 (1972) 21-37
29. LeBail B., Faouzi S., Boussarie L., Balabaud C., Bioulac-Sage P., and Rosenbaum J. Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver. J Pathol 181 (1997) 330-337
30. Lee T.H., Rhim T., and Kim S.S. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 273 (1998) 28805-28812
31. Lefrere J.J., Gozin D., Soulier J.P., Bettan L., Mavier P., Dhumeaux D., et al. Specificity of increased des gamma carboxy prothrombin in hepatocellular carcinoma after vitamin K1 injection. J Hepatol 5 (1987) 27-29
32. Li F., He F., Stehle C.J., Wang Z., Kar S., Finn F.M., et al. Vitamin K uptake in hepatocytes and hepatoma cells. Life Sci 70 (2002) 2085-2100
33. Liebman H.A. Isolation and characterization of a hepatoma-associated abnormal (des-γ-carboxy)prothrombin. Cancer Res 49 (1989) 6493-6497
34. Liebman H.A., Furie B.C., Tong M.J., Blanchard R.A., Lo K.J., Lee S.D., et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310 (1984) 1427-1431
35. Michalopoulos G.K., and DeFrances M. Liver regeneration. Science 276 (1997) 60-66
36. Miyazawa K., Yaguchi M., Funato K., Gotoh A., Kawanishi Y., Nishizawa Y., et al. Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 15 (2001) 1111-1117
37. Mooney D., Hansen L., Vacanti J., Langer R., Farmer S., and Ingber D. Switching from differentiation to growth in hepatocytes: control by extracellular matrix. J Cell Physiol 151 (1992) 497-505
38. Nagaki M., Sugiyama A., Naiki T., Ohsawa Y., and Moriwaka H. Control of cyclins, cyclin-dependent kinase inhibitors, p21 and p27, cell cycle progression in rat hepatocytes by extracellular matrix. J Hepatol 32 (2000) 488-496
39. Nakao A., Virji A., Iwaki Y., Carr B., Iwatsuki S., and Starzl E. Abnormal prothrombin (des-γ-carboxy-prothrombin) in hepatocellular carcinoma. Hepatogastroenterology 38 (1991) 450-453
40. Nishikawa Y., Carr B.I., Wang M., Kar S., Finn F., Dowd P., et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J Biol Chem 270 (1995) 28304-28310
41. Oguro A., Taniguchi H., Daidoh T., Itoh A., Tsukuda N., and Takahashi T. Factors relating to coagulation, fibrinolysis and hepatic damage after liver resection. HPB Surg 7 (1993) 43-49
42. Otsuka M., Kato N., Shao R.X., Hoshida Y., Ijichi H., Koike Y., et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 40 (2004) 243-251
43. Oztopcu P., Kabadere S., Mercangoz A., and Uyar R. Comparison of vitamins K1, K2 and K3 effects on growth of rat glioma and human glioblastoma multiforme cells in vitro. Acta Neurol Belg 104 (2004) 106-110
44. Pelton J.J., Hoffman J.P., and Eisenberg B.L. Comparison of liver function tests after hepatic lobectomy and hepatic wedge resection. Am Surg 64 (1998) 408-414
45. Poulsen H.E., Gaub J., and Iversen J. Changes in quantitative measures of hepatic function after 90% hepatectomy in rats. Eur J Clin Invest 15 (1985) 285-289
46. Rahman S., Patel Y., Murray J., Patel K.V., Sumathipala R., Sobel M., et al. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signaling pathway in endothelial cells. BMC Cell Biol 6 (2005) 8
47. Rhim T.Y., Park C.S., Kim E., and Kim S.S. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun 252 (1998) 513-516
48. Russell W.R., and Bucher N.L. Vasopressin modulates liver regeneration in Brattleboro rats. Am J Physiol 245 (1983) G321-G324
49. Sawada N., Tomomura A., Sattler C.A., Sattler G.L., Kleinman H.K., and Pitot H.C. Extracellular matrix components influence DNA synthesis of rat hepatocytes in primary culture. Exp Cell Res 167 (1986) 458-470
50. Scott D.L., Bedford P.A., and Walton K.W. The preparation of plasma fibronectin antigen and antiserum. J Immunol Methods 43 (1981) 29-33
51. Seglen P.O. Preparation of isolated rat liver cells. Methods Cell Biol 13 (1976) 29-83
52. Sell S., and Ruoslahti E. Expression of fibronectin and laminin in the rat liver after partial hepatectomy, during carcinogenesis and in transplantable hepatocellular carcinomas. J Natl Cancer Inst 69 (1982) 1105-1114
53. Shah D.V., Engelke J.A., and Suttie J.W. Abnormal prothrombin in the plasma of rats carrying hepatic tumors. Blood 69 (1987) 850-854
54. Shibayama-Imazu T., Sakairi S., Watanabe A., Aiuchi T., Nakajo S., and Nakaya K. Vitamin K(2) selectively induced apoptosis in ovarian TYK-nu and pancreatic MIA PaCa-2 cells out of eight solid tumor cell lines through a mechanism different from geranylgeraniol. J Cancer Res Clin Oncol 129 (2003) 1-11
55. Smiles A.M., Jenny N.S., Tang Z., Arnold A., Cushman M., and Tracy R.P. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb Haemost 87 (2002) 614-621
56. Sun L.K., Yoshii Y., and Miyagi K. Cytotoxic effect through fas/APO-1 expression due to vitamin K in human glioma cells. J Neurooncol 47 (2000) 31-38
57. Suzuki M., Shiraha H., Fujikawa T., Takaoka N., Ueda N., Nakanishi Y., et al. Des-γ-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 280 (2005) 6409-6415
58. Szendroi M., and Lapis K. Fibronectin in differential diagnosis of primary hepatomas and carcinoma metastases in the liver. Acta Morphol Hung 33 (1985) 101-109
59. Tabarin A., Bioulac-Sage P., Boussarie L., Balabaud C., de Mascarel A., and Grimaud J.A. Hepatocellular carcinoma developed on noncirrhotic livers. Sinusoids in hepatocellular carcinoma. Arch Pathol Lab Med 111 (1987) 174-180
60. Taper H.S., Jamison J.M., Gilloteaux J., Summers J.L., and Calderon P.B. Inhibition of the development of metastases by dietary vitamin C:K3 combination. Life Sci 75 (2004) 955-967
61. Theret N., Musso O., Turlin B., Lotrian D., Bioulac-Sage P., Campion J.P., et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34 (2001) 82-88
62. Torbenson M., Wang J., Choti M., Ashfaq R., Maitra A., Wilentz R.E., et al. Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol 15 (2002) 826-830
63. Torimura T., Ueno T., Inuzuka S., Kin M., Ohira H., Kimura Y., et al. The extracellular matrix in hepatocellular carcinoma shows different localization patterns depending on the differentiation and the histological pattern of tumors: immunohistochemical analysis. J Hepatol 21 (1994) 37-46
64. Tsai S.L., Huang G.T., Yang P.M., Sheu J.C., Sung J.L., and Chen D.S. Plasma des-γ-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 11 (1990) 481-487
65. Virji M.A., Piper M., and Carr B.I. Alpha-fetoprotein (AFP) and des-gamma-carboxy-prothrombin (DCP) in hepatocellular carcinoma (HCC) and chronic liver diseases. Hepatology 16 (1992) 538
66. Wallin R., and Martin L.F. Warfarin poisoning and vitamin K antagonism in rat and human liver. Biochem J 241 (1987) 389-396
67. Wang Z., Wang M., Finn F., and Carr B.I. The growth inhibitory effects of vitamin K and their actions on gene expression. Hepatology 22 (1995) 876-881
68. Warner E.D. Plasma prothrombin: effect of partial hepatectomy. J Exp Med 68 (1938) 831-835
69. Weitz I.C., and Liebman H.A. Des gamma carboxy (abnormal) prothrombin and hepatocellular carcinoma, a critical review. Hepatology 8 (1993) 990-997
70. Yamanaka Y., Yamano M., Yasunaga K., Shike T., and Uchida K. Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats. Thromb Res 57 (1990) 205-214
71. Yildirim S.I., and Pouslen H.E. Quantitative liver functions after 70% hepatectomy. Eur J Clin Invest 11 (1981) 469-472
72. Yokoyama T., Miyazawa K., Yoshida T., and Ohyashiki K. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines. Int J Oncol 26 (2005) 33-40
73. Yoshida T., Miyazawa K., Kasuga I., Yokoyama T., Minemura K., Ustumi K., et al. Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer. Int J Oncol 23 (2003) 627-632
74. Yoshiji H., Kuriyama S., Noguchi R., Yoshiji J., Ikenaka Y., Yanase K., et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol 42 (2005) 687-693
75. Zhao M., Laissue J.A., and Zimmermann A. Tenascin and type IV collagen expression in liver cell dysplasia and in hepatocellular carcinoma. Histol Histopathol 11 (1996) 323-333